Liprolog Mix25 (Insulin Lispro)

Insulin lispro mimics natural insulin by binding to insulin receptors on muscle, fat and liver cells. This activates intracellular pathways that move glucose‑transport proteins to the cell surface, increasing glucose uptake, while simultaneously suppressing liver glucose production, leading to a swift reduction in blood sugar after injection.

The dose of Liprolog Mix25 is individualized. A qualified healthcare professional determines the amount, timing and frequency based on the patient’s age, weight, renal function, carbohydrate intake and overall glycaemic targets. Patients should follow the prescriber’s written instructions and not adjust the dose on their own.

Safety data for insulin lispro in pregnancy and lactation are limited. It may be used when the expected benefit to the mother outweighs potential risks to the fetus or infant. Decisions should be made by the prescribing clinician in consultation with obstetric and neonatal specialists.

To request Liprolog Mix25, visit the product page on gnhindia.com, enter the desired quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and any required import documentation.

Liprolog Mix25 (insulin lispro) shares the rapid onset and short duration characteristic of rapid‑acting analogues such as insulin aspart and insulin glulisine. Its molecular modifications reduce self‑association, allowing faster absorption. Clinical efficacy and safety are comparable, with choice often based on physician preference, patient response, and formulary considerations.

Unopened vials or pens of Liprolog Mix25 should be stored in a refrigerator at 2 °C to 8 °C, protected from light, and must not be frozen or shaken. Once in use, the product may be kept at controlled room temperature (up to 30 °C) for a limited period as specified in the package insert.

Liprolog Mix25 is given by subcutaneous injection, typically into the abdomen, thigh or upper arm. The injection should be performed using a sterile needle or pen device, rotating sites to avoid lipodystrophy. Patients should be instructed on proper technique, timing relative to meals, and disposal of sharps according to local regulations.

The most serious risks include severe hypoglycemia, which can cause confusion, seizures or loss of consciousness, and allergic reactions ranging from urticaria to anaphylaxis. Prompt recognition and treatment are essential. Patients should be educated on symptom awareness, have access to rapid‑acting glucose sources, and carry emergency glucagon if prescribed.

Liprolog Mix25 is contraindicated in individuals with a known hypersensitivity to insulin lispro or any of the product’s excipients. It should also be avoided in patients with severe hypoglycemia unawareness or those who cannot reliably monitor blood glucose. Clinicians must assess each patient’s medical history before initiating therapy.